



Presentation of the Digital Health Acceleration Strategy / Expected Fast Track for Digital Medical Devices


October 19, 2022

Louisa Stüwe


Ministerial Digital Health Delegation

French digital health implementation roadmap

Health + medico-social + social dimensions




The Digital Health Acceleration Strategy aligned with other national digital health funding strategies



A EUR 670 MILLION STRATEGY LAUNCHED ON 18 OCTOBER 2021

Digital Health Acceleration Strategy

SUPPORTING DIGITAL HEALTH FOR THE ENTIRE INNOVATION PROCESS
A EUR 670 MILLION STRATEGY LAUNCHED ON 18 OCTOBER 2021



Public consultation:
 429 responses — 50 qualitative interviews —
 6 months of interdepartmental work

Calls for expression of interest

Paving the way to a fast-track DMD access in France


PRIOR EXPERIMENTATIONS TO A NATIONAL TRANSITIONAL AND TEMPORARY ONE-YEAR REIMBURSEMENT ACCESS SCHEME FOR DIGITAL MEDICAL DEVICES AND TELEMEDICINE IN FRANCE



- France has been looking at improving care pathways since 2018 by experimenting telemonitoring prior to reimbursement (ETAPES program - Telemedicine Experimentation for the Improvement of Healthcare Pathways)
- The health technology assessment of the program was coordinated by the French National Authority for Health (Haute Autorité de Santé, HAS)
- Transitioning from ETAPES, the French government paved the way to implement a fast track reimbursement for DMDs by 2022 in its 2022 Social Security Funding Bill of December 2021. *Ministerial order to implement the article is pending as of October 19, 2022*
- More information on G_NIUS

Paving the way to a fast-track DMD access in France

IMPLEMENT EARLY ACCESS FOR CE-MARKED DIGITAL DEVICES FOR INDIVIDUAL USE THAT MEET THE CRITERIA FOR INCLUSION ON THE LIST OF PRODUCTS AND SERVICES AND FOR REMOTE MONITORING DEVICES



- For products already **CE marked**

- For Digital Therapeutics and innovative telemonitoring solutions with **clinical evidence**

- **Data interoperability and security standards requirement**

A Fast Track preliminary access

- Accelerated access to reimbursement
- 1 year to apply for normal reimbursement pathway
- Initial fixed price, tailored after 1 year


Guidelines in France

IN FRANCE, THE NATIONAL HEALTH AUTHORITY HAS PUBLISHED A CLASSIFICATION OF DMDS ACCORDING TO THEIR FUNCTIONALITIES, INTENDED USER AND AUTONOMY

Guidelines by the National Health Authority (HAS):


- Medical device evaluation by the CNEDiMTS (Medical Device and Health Technology Evaluation Committee): Guide to the specific features of clinical evaluation of a connected medical device (CMD) in view of its application for reimbursement [Link](#)
- Methodology for the clinical development of medical devices [Link](#)
- Analysis grid for the AI component in medical devices [Link](#)
- Real-world studies for the assessment of medicinal products and medical devices [Link](#)
- Guidelines for telemonitoring on 5 chronic diseases [Link](#) (In French)
- Functional classification, according to their intended use, of digital solutions used in the context of medical and paramedical care [Link](#)

Guidelines by the National eHealth Agency (ANS): to be published by the end of 2022



Fast track access for DMDs access in the EU

BOTH GERMAN AND FRENCH NATIONAL REGULATIONS SUPPORT BROADER PATIENT ACCESS TO INNOVATIVE DMDs, USING DIFFERENT SCOPES



Launch of a European Taskforce

ACCELERATE EUROPEAN MARKET ACCESS THROUGH CLINICAL EVALUATION CRITERIA HARMONISATION FOR DIGITAL MEDICAL DEVICES (DMDS)

In April 2022 under the digital health agenda of the French presidency of the Council of the European Union, a new **European taskforce** has been launched based on several conferences organized by EIT Health with input from both **France and Germany**.

Mission:

- To **harmonize the innovative health technology assessment procedures** with the overall goal to enable a harmonised approach for European assessment supporting national appraisal and reimbursement by statutory health insurance organisations for distinct subclasses of DMDS.
- The taskforce seeks to advise the HTA Coordination Group (HTAR) of EunetHTA, national responsible authorities and agencies, innovators and policy makers – aligned with EU medical device regulators – on the development of a joint DMD assessment procedure, including the definition of DMDs based on their application purpose and evaluation categories.




European Taskforce Rationale

TOWARDS A COMMON EUROPEAN MARKET FOR DIGITAL HEALTH



Framework of the **Regulation on Health Technology Assessment (HTA) regulation**, a deliverable of the EU Pharmaceutical Strategy, applicable from January 2025.



➔ By developing a **joint approach** producing concrete outputs that can be used in the Member States, duplication of assessments can be avoided, patient access to innovative and proven digital health solutions can be accelerated, and health systems improved.

European Taskforce for Harmonised Evaluation of Digital Medical Devices (DMDs)

- The final recommendations for harmonizing clinical criteria and methodologies for evaluating DMDs results from three work packages.

Work package 1	Work package 2	Work package 3 & 4
<ul style="list-style-type: none"> Harmonize the taxonomy of DMDs based on their application scope and evaluation categories 	<ul style="list-style-type: none"> Consensus on determining quantity, quality and the type of evidence that is needed for assessing DMDs 	<ul style="list-style-type: none"> Propose a social health evaluation framework based on pre-requirements (technical, technological, ethical)
Definition/Selection of the DMDs	Joint Evaluation Criteria	Socio-Economic Acceptance
<ul style="list-style-type: none"> Compare definition by national HTA-R (Germany/France/other) Harmonize with MDR Extract similarities <p><u>Propose a joint definition/taxonomy</u></p> <ul style="list-style-type: none"> Therapeutic Application purpose Diagnostic Application purpose <p><i>linked to WP2 evaluation criteria</i></p>	<ul style="list-style-type: none"> Analyse existing Evaluation Criteria <ul style="list-style-type: none"> Clinical evidence categories Outcome/ study methods + design Compare to international evaluation concepts (e.g. EU, UK, USA, etc.) <p><u>Recommend Joint Evaluation Concepts</u></p> <ul style="list-style-type: none"> Patient-centric effects Service-relevant measures <p><i>for the different DMD types (WP1)</i></p>	<ul style="list-style-type: none"> Assess social acceptance criteria (patient engagement, HCP integration, health economic evaluation) Ethical, Legal and Social evaluation regional integration into healthcare services <p><u>Suggest socio-economic evaluation tailored to DMDs</u></p>
External Advisory group		
<p>Contribute to the final suggestions by sharing perspectives of different stakeholders and experiences from real-world examples</p>		

Taskforce Member Institutions



-  **Austrian Institute for Health Technology Assessment, AIHTA (Austria)**
-  **Belgian Health Care Knowledge Centre, KCE (Belgium)**
-  **BioMed Alliance**
-  **Bocconi University (Italy)**
-  **Catalan Agency for Health Quality and Assessment AQuAS (Spain)**
-  **EIT Health (France)**
-  **EUnetHTA**
-  **European Observatory on Health Systems and Policies**
-  **European Patients' Forum, EPF**
-  **Federal Institute for Drugs and Medical Devices (Bundesinstitut f r Arzneimittel und Medizinprodukte, BfArM (Germany)**
-  **FinCCHTA (Finland)**
-  **Finnish Innovation Fund Sitra (Finland)**
-  **French Ministry of Solidarity and Health (France)**
-  **Luxembourg Health Directorate (Luxembourg)**
-  **Medical University of Vienna (Austria)**
-  **National Health Authority, HAS (France)**
-  **University of Liège (Belgium)**
-  **Universtiy of Luxemburg (Luxembourg)**

Taskforce Members



Ahlqvist Johannes
Finnish Innovation
Fund Sitra



Magali Boers
Luxemburg Health
Directorate



Enrico Caiani
Biomed Alliance



Corinne Collignon
Haute Autorité de Santé



Gerry Dawson
Biomed Alliance



Alan Fraser
Biomed Alliance



Lisbet Geris
Biomed Alliance



Marcus Guardian
EUnetHTA



Jari Haverinen
FinCCHTA



Barbara Hoefgen
BfArM



Reinhard Jeindl
Austrian HTA agency



Markus Kalliola
Finnish Innovation
Fund Sitra



**Prof. Dr. Jochen
Klucken**
University of Luxembourg



**Ramon Maspons
Bosch**
Catalan Agency for Health
Quality and Assessment



Dimitra Panteli
European Observatory



Aymeric Perchant
Ministry of Health, France



Martin Posch
Medical University of
Vienna



Aude Rochereau
Haute Autorité de Santé



Lorena San Miguel
Belgian Health Care
Knowledge Center



Valentina Strammiello
European Patients' Forum



Louisa Stuewe
Ministry of Health, France



Rosanna Tarricone
Bocconi University



**Hannah-Marie
Weller**
Bocconi University



Sarah Zohar
Inria – Inserm

European Taskforce for Harmonised Evaluation of Digital Medical Devices (DMDs)

Rapporteur



Prof. Dr. Jochen Klucken
University of Luxembourg

Chairs



Louisa Stüwe
Ministry of Health, France
Aymeric Perchant
Ministry of Health, France



Marcus Guardian
EUnetHTA

Coordination



Jerome Fabiano
EIT Health France



Fruzsina Mezei
EIT Health France

WP1 Taxonomy of DMDs



Magali Boers
Luxemburg Health Directorate



Aude Rochereau
Haute Autorité de Santé

Gerry Dawson
Liesbet Geris
Ramon Maspons
Lorena San Miguel

Dimitra Panteli
Hannah-Marie Weller
Corinne Collignon
Rosanna Tarricone

WP2 Clinical Evidence Model



Sarah Zohar
Inria – Inserm



Corinne Collignon
Haute Autorité de Santé



Barbara Hoefgen
BfArM

Enrico Caiani
Aude Rochereau
Hannah-Marie Weller
Liesbet Geris
Ramon Maspons
Lorena San Miguel

Dimitra Panteli
Martin Posch
Rosanna Tarricone
Reinhard Jeindl
Magali Boers

WP3&4 Socio-Economic aspects data and study designs



Ahlqvist Johannes
Finnish Innovation Fund Sitra



Markus Kalliola
Finnish Innovation Fund Sitra

Johannes Ahlqvist
Barbara Hoefgen
Ramon Maspons
Dimitra Panteli

Hannah-Marie Weller
Rosanna Tarricone
Sijmen van Schagen

External Advisory group



Rosanna Tarricone
Bocconi University



Hannah-Marie Weller
Bocconi University

Calendar: Achievements & Milestones



14th June 2022 :
Agreement on goals and mission statement of Taskforce. Panel discussion at **HIMSS Europe Helsinki**



September 2022:
Preparations for **Horizon Europe 2023 & Joint Action Calls** to obtain funding for the implementation of the recommendations



15th November 2022:
Work starts with the **External Advisory Group** to validate recommendations of the Taskforce

6th May 2022 :
First Taskforce Meeting



1st August 2021 :
Scientific manuscript on vision, mission and working methods of the Taskforce finished (to be published)



26-27th October 2022:
First results of work packages will be presented to the public at **Digital Medicine Conference Luxemburg**



Links

FRENCH EU PRESIDENCY DIGITAL HEALTH – [PRESS KIT](#)

OVERVIEW OF ACHIEVEMENTS OF THE NATIONAL DIGITAL HEALTH STRATEGY 2019 - 2022 - [LINK](#)

STUDY ON DIGITAL HEALTH IN THE EU - [LINK](#)

DIGITAL HEALTH ACCELERATION STRATEGY [PRESS KIT](#)

G_NIUS WEBSITE : [HTTPS://GNIUS.ESANTE.GOUV.FR/](https://gnius.esante.gouv.fr/)

